title: Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.
abstract: Yohimbine is a selective alpha-2 adrenergic antagonist that has been used in the pharmacologic management of erectile dysfunction (ED). We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced worsening of Raynaud's phenomenon when using yohimbine for ED.
authors.affiliation: Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Sindhu
authors.initials: S
authors.lastname: Johnson
authors.forename: John
authors.initials: J
authors.lastname: Iazzetta
authors.forename: Catharine
authors.initials: C
authors.lastname: Dewar
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D000368:Aged; D017675:CREST Syndrome / Q000150:complications*; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000503:physiopathology*; D012720:Severity of Illness Index; D015016:Yohimbine / Q000009:adverse effects*
chemical_list: D000317:Adrenergic alpha-Antagonists; D015016:Yohimbine